Windtree Therapeutics announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure.” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree announces trial design of Phase 2b study of Istaroxime published
- Windtree Therapeutics Appoints New Senior VP and CFO
- Windtree Therapeutics to hold a virtual investor day
- Windtree Therapeutics Updates Investor Presentation Materials
- Windtree Therapeutics announces Phase 2b topline results of istaroxime